New drug combo aims to make bone marrow transplants safer for rare blood cancer
NCT ID NCT07104799
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety and best dose of the drug momelotinib when given before, during, and after a stem cell transplant for people with myelofibrosis, a serious bone marrow disorder. About 28 participants will receive momelotinib pills daily for up to 13 cycles. The goal is to find a dose that limits side effects while supporting transplant recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Momelotinib (a drug taken orally once daily)
What this could lead to
If successful, this could point toward a safer way to use momelotinib alongside stem cell transplants for myelofibrosis, potentially improving outcomes.
What could go wrong
This is a very early (Phase 1) and small (28 people) trial focused on safety and dosing, not yet on effectiveness. It may not lead to a new standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact